NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLPH stock has increased by 98.1% and is now trading at $12.46.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bellerophon Therapeutics.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics Inc (NASDAQ:BLPH) issued its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.02) by $0.13.
View Bellerophon Therapeutics' earnings history.

Shares of Bellerophon Therapeutics reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

3 analysts have issued 1-year price objectives for Bellerophon Therapeutics' shares. Their forecasts range from $30.00 to $35.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $31.67 in the next year. This suggests a possible upside of 154.1% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics.

Press coverage about BLPH stock has trended somewhat negative on Wednesday, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
View the latest news about Bellerophon Therapeutics.

Bellerophon Therapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 389,800 shares, a drop of 18.2% from the June 30th total of 476,600 shares. Based on an average daily trading volume, of 279,200 shares, the short-interest ratio is presently 1.4 days. Approximately 7.2% of the company's stock are short sold.
View Bellerophon Therapeutics' Current Options Chain.

Some companies that are related to Bellerophon Therapeutics include Tocagen (TOCA), AC Immune (ACIU), Syros Pharmaceuticals (SYRS), BioSpecifics Technologies (BSTC), Clovis Oncology (CLVS), Urogen Pharma (URGN), Crinetics Pharmaceuticals (CRNX), DURECT (DRRX), XBiotech (XBIT), Protagonist Therapeutics (PTGX), Ocular Therapeutix (OCUL), BioDelivery Sciences International (BDSI), Puma Biotechnology (PBYI), Catalyst Pharmaceuticals (CPRX) and Avid Bioservices (CDMO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Vaxart (VXRT), Novavax (NVAX), VBI Vaccines (VBIV), Opko Health (OPK), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Clovis Oncology (CLVS).

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include DAVENPORT & Co LLC (1.13%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang.
View institutional ownership trends for Bellerophon Therapeutics.

BLPH stock was bought by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin, and Theodore T Wang.
View insider buying and selling activity for Bellerophon Therapeutics.

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLPH stock can currently be purchased for approximately $12.46.

Bellerophon Therapeutics has a market capitalization of $118.37 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]